EP0809651A1 - Inhibiteurs de la thrombine - Google Patents

Inhibiteurs de la thrombine

Info

Publication number
EP0809651A1
EP0809651A1 EP96903987A EP96903987A EP0809651A1 EP 0809651 A1 EP0809651 A1 EP 0809651A1 EP 96903987 A EP96903987 A EP 96903987A EP 96903987 A EP96903987 A EP 96903987A EP 0809651 A1 EP0809651 A1 EP 0809651A1
Authority
EP
European Patent Office
Prior art keywords
alkyl
pro
aryl
mes0
amb
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP96903987A
Other languages
German (de)
English (en)
Inventor
Werner Seitz
Helmut Mack
Thomas Zierke
Hans-Joachim Böhm
Hans Wolfgang HÖFFKEN
Stefan Koser
Thomas Pfeiffer
Wilfried Hornberger
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Abbott GmbH and Co KG
Original Assignee
BASF SE
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE1995104504 external-priority patent/DE19504504A1/de
Priority claimed from DE1995106610 external-priority patent/DE19506610A1/de
Application filed by BASF SE filed Critical BASF SE
Publication of EP0809651A1 publication Critical patent/EP0809651A1/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0812—Tripeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06026—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atom, i.e. Gly or Ala
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06034—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/0606—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing heteroatoms not provided for by C07K5/06086 - C07K5/06139, e.g. Ser, Met, Cys, Thr
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06078—Dipeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06104—Dipeptides with the first amino acid being acidic
    • C07K5/06113—Asp- or Asn-amino acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06191—Dipeptides containing heteroatoms different from O, S, or N
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Definitions

  • the present invention relates to peptidic p-amidino-benzylamides with N-terminal sulfonyl or aminosulfonyl residues, their preparation and their use as thrombin inhibitors.
  • EP 601 459, EP 672 658, WO 94/29336 and WO 95/23609 describe peptidic thrombin inhibitors.
  • the present invention relates to thrombin inhibitors of the formula I NH
  • R 1 S0 2 AB NH D I NH 2 and their stereoisomers and their salts with physiologically compatible acids, in which the amidine function can be in mono- or bisprotected form and in which the substituents have the following meanings:
  • R 1 OH, -CC 20 alkyl, -C-C 3 fluoroalkyl, C 3 -C 6 cycloalkyl, aryl-Cx-Cio-alkyl, aryl, heteroaryl, R 2 OOC- (CH 2 ) n or R 3 R 2 N, where R 2 and R 3 are the same or different and are hydrogen, -CC-alkyl, aryl, aryl -CC-C ⁇ o-alkyl or together a C -C 7 alkylene chain, to which an aryl or heteroaryl radical is optionally condensed is or which may contain a heteroatom (0, S, NH or substituted N) and n is the number 1, 2, 3 or 4,
  • R 4 is hydrogen, C 8 -C 8 -alkyl, C 3 -C 7 -cycloalkyl, aryl or aryl-C 1 -C 3 -alkyl,
  • R 5 are hydrogen, C 8 alkyl, C 3 -C 7 -cycloalkyl or C 3 -C 7 - cycloalkyl-CH 2 -, where a CH, NR 6 2 group may be replaced in the ring by 0, S, Bicycloalkyl- (CH 2 ) 0 , ⁇ . A ⁇ amantyl- (CH 2 ) o- ⁇ .
  • R 4 and R 5 together form a C -C ⁇ alkylene chain which may contain a fused-on aryl radical
  • R 10 , R 11 are H - C 1 -C 4 -alkyl or R 15 0, where R 9 and R 10 or R 11 together form a fused-on phenylene ring or an alkylene chain consisting of 3 to 5 carbon atoms in which one or two carbon atoms can be replaced by oxygen,
  • R 12 is H or -CC 4 alkyl
  • R 13 C 1 -C 4 -alkyl, phenyl-C 1 -C 4 -alkyl, R 15 C0, CF 3 CO, CF 5 CO, R 15 0CH 2 , R 15 OOC, R 15 OCH 2 CO, R 15 OOCCO or R 15 NHCOCO means
  • R 14 H C 1 -C 4 alkyl, F, Cl, Br, N0 2 , R 15 0, R 15 OOC, R 15 OCH 2 , R 15 NH, R 15 CONH, R 15 NH-CO or R 15 OOCCH 2 0 is and
  • W, X, Y, Z represent CH or N, but at least one of the radicals W, X, Y or ZN is and the ring in VI can be substituted by 1 or 2 of the following radicals: -C 4 alkyl, OH , OC 1 -C alkyl, CF 3 , F, Cl, Br,
  • aryl throughout refers to mono- or bicyclic aromatic groups containing 6 to 10 carbon atoms in the ring system, e.g. Phenyl or naphthyl, and can be provided with up to three identical or different substituents.
  • heteroaryl refers everywhere to 5- or 6-membered aromatic rings which can contain 1 or 2 heteroatoms such as N, 0 or S and to which an aryl ring, for example a phenyl ring, can be fused.
  • cycloalkyl means saturated cyclic hydrocarbon radicals having 3 to 7 carbon atoms, for example cyclopentyl, cyclohexyl, cycloheptyl, the rings being substituted by halogen, C 1 -C 4 alkyl and OC 1 -C 4 alkyl could be.
  • R 1 OH, Ci-Cio-alkyl, CF 3 CH 2 , phenyl, naphthyl, phenyl-Ci-C 4 -alk (especially benzyl and phenethyl), naphthyl-C ! -C 4 alkyl, pyridyl, isoquinolyl, NH, C ⁇ -C 4 -mono- or Dialkyla ino, piperidinyl.
  • A Glycine, alanine, valine, leucine, isoleucine, phenyl or
  • Serine, homoserine, threonine, the carboxyl or hydroxyl group can be esterified or etherified by a C 1 -C 8 -alkylres.
  • the amino acids A are preferably in the D configuration.
  • the fragments are B beso • nders -configuration before.
  • R 9 Cl, Br, N0 2 , R 15 0, R 15 OOC, R 15 OCH 2 , R 15 NH, R 15 CONH or
  • R 15 is OOCCH 2 0, where R 15 is H, C 1 -C 6 -alkyl, benzyl or phenyl,
  • R 1 H ⁇ -C 4 -alkyl or R 15 0.
  • R 1 HO, CH 3 , CH 3 -CH 2 . CH 3 - (CH 2 ) 3 , CF 3 -CH 2 , phenyl, benzyl,
  • A Cyclohexylglycine or cyclohexylalanine, tetrahydropyran-4-ylglycine, tetrahydropyran-4-ylvaline, dicyclohexyl- or diphenylalanine or phenylalanine, the phenyl rings being substituted by up to 3 identical or different CH 3 O, CH 3 , HO, F or Cl radicals can be substituted, serine or tert. -Butylserine.
  • the amino acids are preferably in the D configuration.
  • Fragments B are preferably L-configured.
  • R 9 Cl, CH 3 O or HO
  • R 10 H, CE 3 or CH 3 0
  • R 1 OH, Ci-Cio-alkyl, CF 3 CH 2 , phenyl, naphthyl, phenyl-Ci-C 4 -alkyl (especially benzyl and phenethyl), naphthyl-C ⁇ -C 4 alkyl,
  • Pyridyl isoquinolyl, NH, C ⁇ -C 4 mono- or dialkylamino, piperidinyl.
  • the amino acids A are preferably in the D configuration.
  • Fragments B are preferably L-configured.
  • R 1 HO, CH 3 , CH 3 -CH 2 , CH 3 - (CH 2. 3 , CF 3 -CH 2 , phenyl, benzyl, phenethyl, pyridyl, (CH 3 ) 2 N, CH 3 -NH , NH 2 and piperidinyl,
  • A Cyclohexylglycine or cyclohexylanine, tetrahydropyran-4-ylglycine, tetrahydropyran-4-ylvaline,, dicyclohexyl- or diphenylalanine or phenylalanine, the phenyl rings passing through up to 3 identical or different CH 3 O, CH 3 , HO, F or Cl residues can be substituted, serine or ter. -Butylserine.
  • the amino acids are preferably in the D configuration.
  • the fragments B are preferably configured.
  • R 1 OH, Cx-Cio-alkyl, CF 3 CH 2 , phenyl, naphthyl, phenyl-C ⁇ -C-alkyl (especially benzyl and phenethyl), naphthyl-C 1 -C 4 alkyl,
  • Pyridyl isoquinolyl, NH 2 , -C 4 -C mono- or dial ylamino, piperidinyl.
  • the amino acids A are preferably in the D configuration.
  • Fragment B is preferably L-configured.
  • R 1 OH, Ci-Cio-alkyl, CF 3 CH 2 , phenyl, naphthyl, phenyl-C x -C 4 -alkyl (especially benzyl and phenethyl), naphthyl-C 1 -C 4 -alkyl, pyridyl, isoquinolyl, NH, -CC mono- or dialkylamino, piperidinyl.
  • A Glycine, alanine, valine, eucine, isoleucine, phenyl or
  • the amino acids are preferably in the D configuration.
  • the fragments B are preferably configured.
  • R ' CH 3 or CH 3 0
  • MeS0 2 - (D) Chg-Pro-NH- (6-am-2-Cl) -3-pic MeS0 2 - (D) Chg-Pro-NH- (2-am-4,6- (MeO) 2 -5-pyrim) methyl
  • AIBN Azobisisobutyrodintril on: A idino Ala: Alanine
  • Aze Azetidine carboxylic acid
  • Boc tert. -Butyloxycarbonyl Bz: benzyl
  • Chg cyclohexylglycine
  • Hyp hydroxyproline 2-ind: 2 indoline carboxylic acid
  • Leu Leucine napme: Naphthylmethyl
  • NBS N-bromosuccinimide
  • Ph phenyl Phe: phenylalanine
  • proline pyr 3,4-pyrroline-2-carboxylic acid
  • Tbg tert. -Butylglycine
  • the invention further relates to the compounds of the formulas VII, VIII, IX and X,
  • the compounds of the formula I can be present as such or in the form of their salts with physiologically tolerated acids.
  • acids are: hydrochloric acid, citric acid, tartaric acid, lactic acid, phosphoric acid, methanesulfonic acid, acetic acid, formic acid, maleic acid, fumaric acid, maleic acid, succinic acid, hydroxy succinic acid, sulfuric acid, glutaric acid,
  • Aspartic acid 3-pyruvic acid, benzoic acid, glucuronic acid, oxalic acid, ascorbic acid and acetylglycine.
  • the amidine function in the compounds I can be mono- or bis-protected by an amino protecting group. Cbz and BOC groups are particularly suitable as a protective group. The same applies to the amidine function in compounds VIII.
  • the compounds I can be prepared starting from the ⁇ -amino acid HA-OH or from the N-protected cyclic amino acid B-OH according to reaction schemes I or II.
  • R 16 H or C 1 -C 4 alkyl
  • R 17 C1-C4 alkyl, preferably methyl or t-3utyl
  • Ria N or
  • P is a protecting group, preferably t-butoxycarbonyl (Boc) or benzyloxycarbonyl (Cbz).
  • the protected amino acids PA-OH and HB-OR 17 can be coupled to the dipeptide PAB-OR 17 and then, after splitting off P with R 1 S0 2 C1 or from R 17 , can be reacted with compounds of the formulas VII and VIII, where the reaction sequence is arbitrary.
  • R 1 -S0 2 -A-OH can also be used directly
  • HB NH DR 18 can be coupled to end product I or intermediate VII or IX.
  • amidine-containing intermediates are used in protected form in the above reaction sequences, the protective group (s) are split off at the final stage.
  • R 18 is an amide
  • Boc protective groups are removed hydrogenolytically with HCl / dioxane or CF 3 COOH / methylene chloride, Cbz protective groups or with HF.
  • the saponification of ester functions is carried out with NaOH or LiOH in an alcoholic solvent such as methanol or ethanol.
  • t-Butyl esters are saponified with acids, for example CF 3 COOH.
  • reaction with the sulfonyl chlorides R 1 -S0 2 C1 in the presence of an organic base such as triethylamine, pyridine or N, N-diisopropylethylamine is carried out in organic solvents such as CH 2 CI 2 , THF or DMF.
  • organic solvents such as CH 2 CI 2 , THF or DMF.
  • the reaction is carried out in the presence of aqueous alkali metal hydroxide or carbonate solutions.
  • amidines are prepared from the nitrile precursors by the classic Pinner synthesis (R. Roger and DG Neilson, Chem. Rev. 1961, 61, 179) or preferably by a modified Pinner synthesis which proceeds via imino-thioester salts as an intermediate stage (H. Vieweg et al., Pharmacy 1984, 39, 226).
  • the catalytic hydrogenation of N-hydroxyamidines, which are accessible by adding hydroxylamine to the cyano group, with Raney Ni or Pd / C in alcoholic solvents also leads to amidines (BJ Broughton et al., J. Med. Chem. 1975, 18 , 1117).
  • the new compounds can continue to be used for the therapy and prophylaxis of thrombin-dependent thromboembolic events such as deep venous thrombosis, pulmonary embolism, myocardial or cerebral infarction and unstable angina, and for the therapy of disseminated intravascular coagulation (DIC). They are also suitable for combination therapy with thrombolytics such as streptokinase, urokinase, prourokinase, t-PA, APSAC and other plasminogen activators to shorten the reperfusion time and extend the reocclusion time.
  • thrombin-dependent thromboembolic events such as deep venous thrombosis, pulmonary embolism, myocardial or cerebral infarction and unstable angina
  • DIC disseminated intravascular coagulation
  • thrombolytics such as streptokinase, urokinase, prourokinase, t-PA, APS
  • the compounds according to the invention can be administered in the usual way orally or parenterally (subcutaneously, intravenously, intramuscularly, intraperitoneally, rectally). It can also be applied with vapors or sprays through the nasopharynx.
  • the dosage depends on the age, condition and weight of the patient and on the type of application.
  • the daily dose of active ingredient per person is between about 10 and 2000 mg with oral administration and between about 1 and 200 mg with parenteral administration. This dose can be given in 2 to 4 single doses or once a day as a depot form.
  • the new compounds can be used in the customary pharmaceutical application forms, solid or liquid, e.g. as tablets, film-coated tablets, capsules, powders, granules, dragees, suppositories, solutions, ointments, creams or sprays. These are manufactured in the usual way.
  • the active ingredients can be processed with the usual pharmaceutical auxiliaries such as tablet binders, fillers, preservatives, tablet disintegrants, flow regulators, plasticizers, wetting agents, dispersants, emulsifiers, solvents, retardants, antioxidants and / or propellants (see H. Sucker et al: Pharmaceutical Technology, Thieme-Verlag, Stuttgart, 1978).
  • the application forms thus obtained normally contain the active ingredient in an amount of 0.1 to 99 percent by weight.
  • nitrile was converted to the amidine via the thioamide step by known processes (DE 4121947). Starting from nitrile, 2.2 g of the thioamide were obtained.
  • the thioamide was dissolved in 150 ml of acetone and left at room temperature for 6 hours after the addition of 7 ml of methyl iodide. After the solvent had been stripped off, the amorphous residue was stirred with dry ether and then dried.
  • the S-methyl-thioimidic acid methyl ester hydroiodide was in
  • reaction mixture was poured into 300 ml of water and extracted several times with ether. After drying with Na 2 S0 4 and distilling off the ether, 6.8 g of yellowish remained Crystals that entered the subsequent reaction without further purification.
  • the compound obtained according to a) was dissolved in 45 ml of tetrahydrofuran and 1.2 ml of water, and 11.2 g of triphenylphosphine were added in portions with stirring. The reaction mixture remained at room temperature overnight. After the solvent had been distilled off, the residue was taken up in 100 ml of ether, the triphenylphosphoxide which had precipitated out was filtered off with suction and the filtrate was adjusted to pH 2 with ethereal hydrochloric acid. The precipitated hydrochloride was suction filtered, washed with ether and digested successively with toluene and hot isopropanol. 4.7 g (40%) of hydrochloride were isolated, mp: 253-256 ° C. (decomposition).
  • the aqueous phase was diluted with water and extracted several times with methyl tert-butyl ether.
  • the aqueous phase was with KHS0 4 solution. acidified and extracted 3 times with CH 2 C1 2 .
  • the oily residue was crystallized from diisopropyl ether / n-hexane (1/3). 28 g of white crystals, mp 145-148 ° C., were isolated.
  • Example 5d Analogously to Example 5d, the protective group was split off from the above Boc compound, reacted with methanesulfonic acid chloride and the cyano group was converted into the amidine. The acetate was isolated in the form of white crystals, mp. 250-256 ° C (dec.), FAB-MS: 465 (M + H + ).
  • Example 8 Analogously to Example 5d, the protective group was split off from the above Boc compound, reacted with methanesulfonic acid chloride and the cyano group was converted into the amidine. The acetate was isolated in the form of white crystals, mp. 149-150 ° C (dec.), FAB-MS: 465 (M + H + ).
  • Propanephosphonic anhydride 50% solution in ethyl acetate was added. The mixture was then stirred overnight at room temperature. The solution was diluted to 150 ml with CH 2 C1 2 , extracted successively with 20% sodium hydrogen sulfate solution and 5% citric acid solution, dried over sodium sulfate and evaporated. The aqueous phases were back extracted three times with CH 2 C1 2 , the organic phase was dried, rotated in and used together with the main product in the subsequent reaction without further purification.
  • the crude product from a) was dissolved in 100 ml of CH 2 C1 2 and, after addition of 10 ml of 5M HCl in ether, stirred for 2 hours at room temperature (TLC control). After complete rotary evaporation in vacuo and codestillation with toluene in vacuo, the crude product was recrystallized from 200 ml of ethanol. This gave 5.03 g and again 0.3 g of product by concentrating the mother liquor. (80.4% of theory). After elemental analysis, the product was in the form of monohydrochloride.
  • the solution was extracted five times with 25 ml of 5% citric acid (according to the DC, there was no longer any diisopropylethylamine in the organic phase), the organic phase was washed several times with saturated sodium bicarbonate solution, dried over sodium sulfate and concentrated in vacuo. To minimize the by-product of propanephosphonic acid, the residue was taken up in ethyl acetate, extracted several times with saturated hydrogen carbonate solution, then dried over sodium sulfate and evaporated. Yield 7.0 g of product solidified to foam (75% of theory).

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Mutual Connection Of Rods And Tubes (AREA)

Abstract

L'invention concerne des inhibiteurs de la thrombine de la formule (I), dans laquelle R1, A, B et D ont la signification donnée dans la description, ainsi que des produits intermédiaires servant à leur préparation. Ces composés (I) s'utilisent pour lutter contre des maladies.
EP96903987A 1995-02-10 1996-02-06 Inhibiteurs de la thrombine Withdrawn EP0809651A1 (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
DE1995104504 DE19504504A1 (de) 1995-02-10 1995-02-10 Heterocyclische Thrombininhibitoren
DE19504504 1995-02-10
DE19506610 1995-02-24
DE1995106610 DE19506610A1 (de) 1995-02-24 1995-02-24 Thrombininhibitoren
PCT/EP1996/000472 WO1996024609A1 (fr) 1995-02-10 1996-02-06 Inhibiteurs de la thrombine

Publications (1)

Publication Number Publication Date
EP0809651A1 true EP0809651A1 (fr) 1997-12-03

Family

ID=26012343

Family Applications (1)

Application Number Title Priority Date Filing Date
EP96903987A Withdrawn EP0809651A1 (fr) 1995-02-10 1996-02-06 Inhibiteurs de la thrombine

Country Status (15)

Country Link
US (1) US5932567A (fr)
EP (1) EP0809651A1 (fr)
JP (1) JPH10513462A (fr)
KR (1) KR19980702112A (fr)
CN (1) CN1173872A (fr)
AU (1) AU706834B2 (fr)
BR (1) BR9607412A (fr)
CA (1) CA2210989A1 (fr)
CZ (1) CZ237697A3 (fr)
EA (1) EA002767B1 (fr)
FI (1) FI973282A (fr)
HU (1) HUP9800634A3 (fr)
MX (1) MX9705970A (fr)
NO (1) NO973657L (fr)
WO (1) WO1996024609A1 (fr)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9900043D0 (sv) * 1999-01-11 1999-01-11 Astra Ab New use
US5705487A (en) * 1994-03-04 1998-01-06 Eli Lilly And Company Antithrombotic agents
US5707966A (en) * 1994-03-04 1998-01-13 Eli Lilly And Company Antithrombotic agents
US5726159A (en) * 1994-03-04 1998-03-10 Eli Lilly And Company Antithrombotic agents
US5710130A (en) * 1995-02-27 1998-01-20 Eli Lilly And Company Antithrombotic agents
US5914319A (en) * 1995-02-27 1999-06-22 Eli Lilly And Company Antithrombotic agents
SE9602263D0 (sv) 1996-06-07 1996-06-07 Astra Ab New amino acid derivatives
US6200967B1 (en) 1996-06-25 2001-03-13 Eli Lilly And Company Anticoagulant agents
CA2258915A1 (fr) 1996-06-25 1997-12-31 Michael Robert Wiley Agents anticoagulants
EP1110968B1 (fr) * 1996-06-25 2003-10-01 Eli Lilly & Company produits intermediaires pour la préparation des Thrombininhibitors comme agents d'anticoagulants
US6262047B1 (en) 1996-10-11 2001-07-17 Cor Therapeutics, Inc. Selective factor Xa inhibitors
US6194435B1 (en) 1996-10-11 2001-02-27 Cor Therapeutics, Inc. Lactams as selective factor Xa inhibitors
US6369080B2 (en) 1996-10-11 2002-04-09 Cor Therapeutics, Inc. Selective factor Xa inhibitors
US6063794A (en) 1996-10-11 2000-05-16 Cor Therapeutics Inc. Selective factor Xa inhibitors
JP2001521524A (ja) * 1997-04-14 2001-11-06 シーオーアール セラピューティクス インコーポレイテッド 選択的Ｘａ因子阻害剤
JP2001523226A (ja) 1997-04-14 2001-11-20 シーオーアール セラピューティクス インコーポレイテッド 選択的Ｘａ因子阻害剤
WO1998046627A1 (fr) 1997-04-14 1998-10-22 Cor Therapeutics, Inc. INHIBITEURS SELECTIFS DU FACTEUR Xa
US7109326B2 (en) 1997-04-15 2006-09-19 Genentech, Inc. Halo-alkoxycarbonyl prodrugs
AR013084A1 (es) 1997-06-19 2000-12-13 Astrazeneca Ab Derivados de amidino utiles como inhibidores de la trombina, composicion farmaceutica, utilizacion de dichos compuestos para la preparacion demedicamentos y proceso para la preparacion de los compuestos mencionados
US6228854B1 (en) 1997-08-11 2001-05-08 Cor Therapeutics, Inc. Selective factor Xa inhibitors
US6333321B1 (en) 1997-08-11 2001-12-25 Cor Therapeutics, Inc. Selective factor Xa inhibitors
US6218382B1 (en) 1997-08-11 2001-04-17 Cor Therapeutics, Inc Selective factor Xa inhibitors
SE9704543D0 (sv) 1997-12-05 1997-12-05 Astra Ab New compounds
KR20000047461A (ko) 1998-12-29 2000-07-25 성재갑 트롬빈 억제제
US6486193B2 (en) 1998-12-31 2002-11-26 Aventis Pharmaceuticals Inc. 3-substituted pyrrolidines useful as inhibitors of matrix metalloproteinases
JP4489976B2 (ja) * 1999-04-09 2010-06-23 ビーエーエスエフ ソシエタス・ヨーロピア 補体プロテアーゼの低分子インヒビター
EP1808440B1 (fr) * 2000-08-11 2011-07-27 Wilex AG Inhibiteurs non covalents d'urokinase et formation de vaisseaux sanguins
NZ518195A (en) * 2000-08-11 2005-04-29 Corvas Int Inc Non-covalent inhibitors of urokinase and blood vessel formation
DE10049937A1 (de) * 2000-10-06 2002-04-11 Knoll Ag Niedermolekulare Inhibitoren von Serinproteasen mit Polyhydroxyalkyl- und Polyhydroxycycloalkylresten
US6716869B2 (en) 2001-12-17 2004-04-06 Pharmacia Corporation Protease inhibitors of the coagulation cascade isolated from Dysidea sponges
AU2003206945A1 (en) * 2002-02-22 2003-09-09 Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V. Use of proteinase inhibitors in the treatment of autoimmune diseases
DE102004022897A1 (de) * 2004-05-10 2005-12-08 Bayer Cropscience Ag Azinyl-imidazoazine
DE102008041214A1 (de) 2008-08-13 2010-02-18 Bayer Cropscience Ag N-substituierte Azinylakyl-azincarboxamide und deren Analoge
US10597863B2 (en) 2018-01-19 2020-03-24 Resource Fiber LLC Laminated bamboo platform and concrete composite slab system

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU675981B2 (en) * 1992-12-02 1997-02-27 Bristol-Myers Squibb Company Guanidinyl-substituted heterocyclic thrombin inhibitors
SE9301916D0 (sv) * 1993-06-03 1993-06-03 Ab Astra New peptides derivatives
AU1025795A (en) * 1994-01-27 1995-08-03 Mitsubishi Chemical Corporation Prolineamide derivatives
ZA951617B (en) * 1994-03-04 1997-02-27 Lilly Co Eli Antithrombotic agents.

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO9624609A1 *

Also Published As

Publication number Publication date
AU4787596A (en) 1996-08-27
AU706834B2 (en) 1999-06-24
CA2210989A1 (fr) 1996-08-15
EA002767B1 (ru) 2002-08-29
NO973657D0 (no) 1997-08-08
FI973282A0 (fi) 1997-08-08
FI973282A (fi) 1997-08-08
CZ237697A3 (cs) 1998-04-15
KR19980702112A (ko) 1998-07-15
NO973657L (no) 1997-10-03
HUP9800634A2 (hu) 1999-06-28
US5932567A (en) 1999-08-03
CN1173872A (zh) 1998-02-18
HUP9800634A3 (en) 2000-04-28
BR9607412A (pt) 1998-07-07
JPH10513462A (ja) 1998-12-22
MX9705970A (es) 1997-11-29
EA199700155A1 (ru) 1997-12-30
WO1996024609A1 (fr) 1996-08-15

Similar Documents

Publication Publication Date Title
EP0809651A1 (fr) Inhibiteurs de la thrombine
KR100223662B1 (ko) 자동 금전 출납기를 사용하여 송금된 돈을 지급하는 전자 송금 시스템 및 방법
AU708001B2 (en) Novel thrombin inhibitors
EP0956294B1 (fr) Inhibiteurs de la thrombine
EP1523493B1 (fr) Nouveaux analogues de tubulysine
DE3211569A1 (de) N-substituierte amidoaminosaeuren und verfahren zu ihrer herstellung
WO1995035309A1 (fr) Nouveaux inhibiteurs de thrombine, leur preparation et leur utilisation
DE69432573T2 (de) Inhibitoren des Endothelin konvertierenden Enzyms
WO1996025426A9 (fr) Nouvelles amidines dipeptidiques utilisees comme inhibiteurs de thrombine
WO1997017362A1 (fr) Nouveaux derives d'acide amine, procede de production correspondant et compositions pharmaceutiques contenant ces composes
EP0796271B1 (fr) p-amidinobenzylamides dipeptidiques a restes n-terminaux sulfonyle ou aminosulfonyle
DE19937721A1 (de) Neue Diketopiperazine
DD151745A5 (de) Verfahren zur herstellung von tripeptiden
EP1051431A1 (fr) Inhibiteurs de la thrombine
EP0133225A2 (fr) Dérivés de peptides et leurs sels, compositions pharmaceutiques les contenant, procédé et produits intermédiaires pour leur production
WO2000061609A2 (fr) Promedicaments d'inhibiteurs de la thrombine
EP1049673A1 (fr) Amidines heterocycliques utilisees comme inhibiteurs de la kallicreine
DE19506610A1 (de) Thrombininhibitoren
DE19504504A1 (de) Heterocyclische Thrombininhibitoren
WO2000061577A1 (fr) Promedicaments d'inhibiteurs de la thrombine
DE2055141A1 (de) Polypeptidverbindungen und Verfahren zu ihrer Herstellung
EP0176999A2 (fr) Dérivés d'amino-acides, leur procédé de préparation et compositions pharmaceutiques

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19970722

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE ES FR GB IT LI NL SE

18D Application deemed to be withdrawn

Effective date: 19981210

18RA Request filed for re-establishment of rights before grant

Effective date: 19990226

18RR Decision to grant the request for re-establishment of rights before grant

Free format text: 19990930 ANGENOMMEN

REG Reference to a national code

Ref country code: DE

Ref legal event code: 8570

D18D Application deemed to be withdrawn (deleted)
17Q First examination report despatched

Effective date: 20000619

GRAH Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOS IGRA

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: ABBOTT GMBH & CO. KG

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

R18D Application deemed to be withdrawn (corrected)

Effective date: 20030713